Search company, investor...

Gemini Technologies

gemtech.com

Stage

Acquired | Acquired

About Gemini Technologies

Gemini Technologies, known as Gemtech, began as a group of designers with roots in the suppressor business going back to 1976. Gemtech's suppressors are in use with all branches of the U.S. military and are also in use by many special operations forces, military, and police around the world. Based in Eagle, Idaho, Gemtech is an International Organization for Standardization (ISO) 9001:2008 certified company and maintains effective rigorous quality assurance systems and processes.

Headquarters Location

335 North Edgewood Lane Suite 150

Eagle, Idaho, 83616,

United States

Missing: Gemini Technologies's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Gemini Technologies's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Gemini Technologies Patents

Gemini Technologies has filed 18 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/21/2017

6/25/2019

Firearm components, Light machine guns, Ammunition, Noise reduction, Military cartridges

Grant

Application Date

2/21/2017

Grant Date

6/25/2019

Title

Related Topics

Firearm components, Light machine guns, Ammunition, Noise reduction, Military cartridges

Status

Grant

Latest Gemini Technologies News

Breast Cancer Proteomic via Laser-Free Microdissection and Gemini Technologies

Jul 30, 2019

Award Information Branch: N/A Award End Date (Contract End Date):N/A Small Business Information DUNS:N/A Abstract DESCRIPTION (provided by applicant): The generation of biologically relevant proteomics data requires samples consisting of homogenous cell populations, in which no unwanted cells of different types and/or development stages obscure the results. The problem is compounded for the analysis of tissue biopsies, since many different cell types are typically present, and small numbers of abnormal cells may lie within or adjacent to unaffected areas. While methods such as laser capture microdissection (LCM) enable the isolation of homogeneous subpopulations of cells, proteomic analysis of LCM-procured specimens is severely constrained by the very low amounts of sample generated. To avoid the limitations of established proteome techniques for analyzing protein extracts obtained from microdissection-procured tissue specimens, an effective discovery-based proteome platform has recently been developed at Calibrant. This proteome platform, called Gemini, combines a unique multidimensional separation system with customized back-end bioinformatics tools, and allows ultrasensitive analysis of minute protein amounts extracted from cells captured by tissue microdissection. This project further aims to employ a novel, laser-free microdissection technique pioneered by our collaborator, Dr. Zhengping Zhuang at the National Institute of Neurological Disorders and Stroke (NINDS), capable of providing enriched, high quality, and reproducible tissue samples. By combining Calibrant's ability to perform proteomic profiling from minute samples with the technology and expertise offered by Dr. Zhuang (NINDS) in tissue microdissection and tumor pathology, the proposed research represents a synergistic effort toward the evaluation and validation of a novel biomarker discovery paradigm for enabling the proteome analysis of cancer cells and their micro-environment in support of cancer research, diagnosis, and treatment. Application of the resulting biomarker discovery platform for studying the molecular mechanisms associated with breast carcinoma at the global level will be realized through a collaboration with Professor Fattaneh A. Tavassoli (Yale University School of Medicine), who will apply more than 30 years of research experience in breast cancer pathology and biology and provide access to a collection of fresh frozen human breast cancer biopsies for biomarker discovery. * Information listed above is at the time of submission. *

Gemini Technologies Frequently Asked Questions (FAQ)

  • Where is Gemini Technologies's headquarters?

    Gemini Technologies's headquarters is located at 335 North Edgewood Lane, Eagle.

  • What is Gemini Technologies's latest funding round?

    Gemini Technologies's latest funding round is Acquired.

  • Who are the investors of Gemini Technologies?

    Investors of Gemini Technologies include Smith & Wesson Holding.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.